This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Turning Point Brands (TPB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Turning Point Brands (TPB) delivered earnings and revenue surprises of 46.67% and 5.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Turning Point Brands (TPB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Turning Point Brands (TPB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) Benefits From Pricing, Oral Tobacco Expansion
by Zacks Equity Research
Altria (MO) strives to expand on! amid consumers' rising preference for low-risk tobacco alternatives. Moreover, strong pricing for tobacco products bodes well.
New Strong Sell Stocks for November 24th
by Zacks Equity Research
BABA, BYND, GLW, DLB, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on November 24, 2021.
Down 18.5% in 4 Weeks, Here's Why Turning Point Brands (TPB) Looks Ripe for a Turnaround
by Zacks Equity Research
Turning Point Brands (TPB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Turning Point Brands (TPB) Tops Q3 Earnings Estimates
by Zacks Equity Research
Turning Point Brands (TPB) delivered earnings and revenue surprises of 2.86% and -3.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Turning Point Brands (TPB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Turning Point Brands (TPB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Philip Morris' (PM) IQOS, Beyond Nicotine Growth Plans On-Track
by Zacks Equity Research
Philip Morris (PM) benefits from the growing market for IQOS devices globally. It is also focused on the expansion of Beyond Nicotine products to support inhaled therapeutics.
Focus on Low-Risk Offerings Drives Altria (MO), Pricing Aids
by Zacks Equity Research
Altria (MO) strives to expand IQOS and on! amid consumers' rising preference on low-risk tobacco alternatives. Moreover, strong pricing for tobacco products is driving revenues.
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris, Altria Group and Turning Point Brands
3 Tobacco Stocks to Watch Out For on RRPs and Pricing Gains
by Vidya Nair
The Zacks Tobacco industry gains from reduced-risk products and solid pricing. Such upsides have been benefiting companies like Philip Morris (PM), Altria (MO) and Turning Point Brands (TPB). However, regulatory headwinds in cigarettes are a concern.
Philip Morris (PM) Strives to Expand IQOS & Beyond Nicotine
by Zacks Equity Research
Philip Morris (PM) is gaining from growing consumer acceptance for IQOS devices. It is on track with the expansion of Beyond Nicotine products to support inhaled therapeutics.
Turning Point Brands (TPB) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Turning Point Brands (TPB) delivered earnings and revenue surprises of 9.09% and 13.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Turning Point Brands (TPB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Turning Point Brands (TPB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) to Divest Ste. Michelle Wine Estates Business
by Zacks Equity Research
Altria's (MO) subsidiary agrees to sell Ste. Michelle Wine Estates business. The move will boost shareholders' value, while aiding in smooth transition of adult smokers to a non-combustible future.
Philip Morris (PM) Up 10% in 3 Months, Gains on Pricing & RRPs
by Zacks Equity Research
Philip Morris (PM) is gaining from rising popularity of IQOS devices. Additionally, pricing power, especially for combustible products, is an upside.
Altria (MO) Gains on Low-Risk Tobacco Offerings, Strong Pricing
by Zacks Equity Research
Altria's (MO) low-risk and oral tobacco offerings are gaining popularity. Moreover, high pricing for tobacco products is an upside.
Philip Morris (PM) Benefits From IQOS Growth & Strong Pricing
by Zacks Equity Research
Philip Morris (PM) gains from growth in the RRPs category, backed by rising popularity of IQOS devices. Additionally, pricing power, especially for combustible products, is an upside.
Altria (MO) Sees Growth in Low-Risk Products, Pricing Aids
by Zacks Equity Research
Altria's (MO) low-risk tobacco offerings such as IQOS and on! are gaining popularity. Moreover, high pricing for tobacco products are an upside..
New Strong Sell Stocks for April 30th
by Zacks Equity Research
ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021
Turning Point Brands (TPB) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Turning Point Brands (TPB) delivered earnings and revenue surprises of 25.00% and 5.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Turning Point Brands (TPB) Ahead of Earnings?
by Zacks Equity Research
Turning Point Brands (TPB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Turning Point Brands (TPB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Turning Point Brands (TPB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) Looks Steady on Low-Risk Products & Strong Pricing
by Zacks Equity Research
Altria (MO) gains from the popularity of low-risk tobacco alternatives such as IQOS. Moreover, strong pricing for tobacco products supports revenues.
Philip Morris (PM) Gains on RRPs Popularity & Pricing Power
by Zacks Equity Research
Philip Morris' (PM) IQOS devices are gaining traction among consumers. Moreover, pricing power, especially for combustible products, is an upside.